IRC
TCRR

Investors Research Corp’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Investors Research Corp’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-15
Closed -$23 – 1135
2023
Q1 		$23 Hold
15
– – ﹤0.01% 1116
2022
Q4 		$15 Hold
15
– – ﹤0.01% 1135
2022
Q3 		$0 Hold
15
– – ﹤0.01% 1160
2022
Q2 		$0 Hold
15
– – ﹤0.01% 1181
2022
Q1 		$0 Hold
15
– – ﹤0.01% 1116
2021
Q4 		$0 Hold
15
– – ﹤0.01% 1068
2021
Q3 		$0 Hold
15
– – ﹤0.01% 1051
2021
Q2 		$0 Buy
+15
New +$303 ﹤0.01% 1032
2020
Q4 		– Sell
-69
Closed -$1K – 1118
2020
Q3 		$1K Buy
+69
New +$1.21K ﹤0.01% 1072

Investors Research Corp's TCRR Position: Q2 2023 in Review

Investors Research Corp sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2023, closing a stake of 15 shares — an estimated $23 sold.

Investors Research Corp first reported a position in TCRR in Q3 2020 and held it in 9 quarters. The position peaked at $1K in Q3 2020. 0 funds tracked by Wall St. Rank hold TCRR as of Q2 2023.

  • Investors Research Corp reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Investors Research Corp sold 15 TCR2 Therapeutics Inc. Common Stock shares in Q2 2023, an estimated $23.
  • Investors Research Corp first reported a position in TCR2 Therapeutics Inc. Common Stock in Q3 2020 and held it in 9 quarters.
  • Investors Research Corp's TCR2 Therapeutics Inc. Common Stock position peaked at $1K in Q3 2020.
  • 0 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2023.

Based on Investors Research Corp's 13F filing for Q2 2023, filed 14 Aug 2023.